Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence
The aim of this project is to conduct a Phase IIb, randomized clinical trial to evaluate the effect of an alpha-7 nicotinic cholinergic receptor partial agonist on cognitive deficits associated with nicotine withdrawal and assess its efficacy as a smoking cessation treatment when used as monotherapy or in conjunction with nicotine patch in a 2×2 design clinical trial.
More information at ClinicalTrials.gov.